Zygnomelia (Acrodynia) – A Complete Patient Guide

Overview

Zygnomelia, historically known as acrodynia or “pink disease,” is a rare, painful peripheral neuropathy that primarily affects children. It is characterized by severe burning pain, swelling, and color changes (often pink or reddish) of the hands and feet. The condition usually follows exposure to elemental mercury, most often from ingestion of mercury‑containing teething powders, folk medicines, or contaminated home remedies. In modern times, outbreaks are uncommon in high‑income nations, but sporadic cases still occur worldwide, especially where mercury‑containing products are still marketed.

Who is affected? Nearly 90 % of reported cases involve children under 5 years of age, with a slight male predominance (≈55 %). Adults can develop a similar syndrome after high‑dose mercury exposure, but the pediatric presentation is classic.

Prevalence: In the United States, estimates from the CDC suggest < 1 case per 100,000 children per year [1]. Outbreaks in the mid‑20th century (e.g., the “pink disease” epidemic of the 1950s) affected several hundred children, largely linked to over‑the‑counter teething powders.[2] Today, most cases are isolated and reported in the medical literature rather than as population‑based data.

Symptoms

Symptoms develop weeks to months after mercury exposure and may progress in three phases. The table below summarizes the typical clinical picture.

Skin and peripheral findings

• Painful erythema – bright pink or reddish discoloration of the palms, soles, and sometimes the distal fingers or toes.
• Burning or “pins‑and‑needles” sensation (paresthesia) that worsens with warmth.
• Swelling (edema) of the affected extremities.
• Hyperhidrosis – excessive sweating of the hands and feet.
• Desquamation – peeling skin after the acute phase.

Systemic manifestations

• Fever – low‑grade, often intermittent.
• Irritability & insomnia – especially in toddlers.
• Lacrimation and photophobia – excessive tearing and sensitivity to light.
• Weight loss & anorexia – due to chronic discomfort.
• Hypertension & tachycardia – reported in 30‑40 % of severe cases.
• Neurologic signs – tremor, ataxia, or peripheral neuropathy beyond the distal extremities (rare).

Timeline of symptom progression

1. Weeks 1‑4 – initial skin changes and mild pain.
2. Weeks 4‑12 – intensifying burning pain, swelling, hyperhidrosis, and systemic signs.
3. Months 3‑6 – gradual resolution with possible residual discoloration or mild neuropathy.

Causes and Risk Factors

Primary cause – elemental mercury poisoning

Elemental mercury (Hg⁰) is a liquid metal that vaporizes at room temperature. Ingestion of mercury‑laced products delivers a dose that is absorbed through the gastrointestinal tract; inhalation of vapor (e.g., from broken thermometers) can also contribute. Once in the bloodstream, mercury binds to sulfhydryl groups in proteins, leading to oxidative stress and inflammation of peripheral nerves and blood vessels.

Common sources

• Traditional or “home” teething powders (historically the most frequent source).
• Folk remedies, skin creams, or ointments containing mercury.
• Contaminated dietary supplements (e.g., some Ayurvedic preparations).
• Accidental ingestion of mercury from broken devices (thermometers, sphygmomanometers).

Risk factors

• Age < 5 years – children have higher gastrointestinal absorption of mercury.
• Socio‑economic factors – use of traditional medicines is more common in low‑income regions.
• Genetic susceptibility – polymorphisms in genes encoding glutathione‑S‑transferases may reduce mercury detoxification.
• Renal insufficiency – impairs mercury excretion.

Diagnosis

Diagnosis rests on a combination of clinical suspicion, exposure history, and laboratory confirmation.

1. Detailed history

• Ask about ingestion of teething powders, folk remedies, or exposure to broken mercury devices.
• Timeline of symptom onset relative to possible exposure.

2. Physical examination

• Observe characteristic pink erythema, edema, and hyperhidrosis of distal extremities.
• Neurologic assessment for peripheral neuropathy.

3. Laboratory tests

• Blood mercury level – values > 10 µg/L in children are generally considered elevated; symptomatic patients often exceed 20‑30 µg/L.[3]
• Urine mercury concentration – useful for monitoring treatment response; spot urine > 50 µg/L is abnormal.
• Renal function (serum creatinine, BUN) – to evaluate mercury‑related nephrotoxicity.

4. Ancillary studies (when indicated)

• Electromyography (EMG) / Nerve conduction studies – may show peripheral sensory neuropathy.
• Skin biopsy – rarely performed; can demonstrate perivascular inflammation.
• Imaging – not routinely needed, but chest X‑ray may rule out pulmonary mercury vapor inhalation in occupational exposures.

Diagnostic criteria (adapted from WHO & CDC)

1. Documented exposure to elemental mercury within the preceding 6 months.
2. Typical clinical triad: painful pink discoloration of extremities, hyperhidrosis, and systemic signs (fever, irritability).
3. Elevated blood or urine mercury concentrations above age‑specific reference ranges.
4. Exclusion of alternative diagnoses (e.g., cellulitis, erythema multiforme, Kawasaki disease).

Treatment Options

Management focuses on rapid removal of mercury, symptomatic relief, and prevention of long‑term sequelae.

1. Chelation therapy

Agent	Indication	Dosage (children)	Key notes
Dimercaprol (British Anti‑Lewisite, BAL)	Severe intoxication (blood Hg > 30 µg/L)	0.1 mL/kg IM every 4 h for 5‑7 days	Effective but painful IM injections; monitor for hypertension.
2,3‑Dimercaptosuccinic acid (DMSA, Succimer)	Mild‑moderate cases or after BAL	10 mg/kg PO every 8 h for 5 days, then 10 mg/kg PO every 12 h for 14‑21 days	Oral, better tolerated; FDA‑approved for pediatric mercury poisoning.
2,3‑Dimercapto‑1‑propanesulfonic acid (DMPS)	Alternative to DMSA when renal impairment	10 mg/kg PO every 8 h	Limited US availability; used in Europe & Asia.

**Monitoring:** Repeat blood/urine mercury levels every 2‑3 days during chelation and weekly after completion until levels normalize.

2. Symptomatic management

• Analgesics – acetaminophen or ibuprofen for mild pain; short‑course opioids reserved for severe burning pain.
• Topical agents – cool compresses, calamine lotion, or 1 % hydrocortisone cream to reduce erythema and itching.
• Antihistamines – diphenhydramine for associated pruritus.
• Beta‑blockers (e.g., propranolol) – can help control hypertension and tachycardia.

3. Supportive care

• Hydration and nutrition to counter weight loss.
• Sleep hygiene and a calm environment to reduce irritability.
• Physical therapy if motor weakness persists.

4. Follow‑up

Patients should be re‑evaluated at 1, 3, and 6 months post‑treatment. Persistent neuropathy may require referral to a pediatric neurologist.

Living with Zygnomelia (acrodynia)

Even after successful treatment, families may need practical strategies to manage lingering symptoms and prevent recurrence.

Daily management tips

• Skin care – keep the affected hands/feet clean, moisturized, and avoid hot water that can exacerbate burning.
• Temperature regulation – cool the extremities with cold packs (15‑20 min) before bedtime to lessen night‑time pain.
• Footwear – use soft, breathable shoes and avoid tight socks that increase edema.
• Nutrition – high‑protein, antioxidant‑rich foods (berries, leafy greens) support mercury detoxification.
• Hydration – ≥ 1 L water daily aids renal clearance of mercury.
• Medication adherence – complete the full chelation course even if symptoms improve.
• School accommodations – arrange for rest periods, easy access to a cool environment, and a nurse who knows the child's condition.
• Emotional support – counseling or support groups for parents can alleviate anxiety about the disease.

When to contact your pediatrician

• New or worsening pain after cessation of chelation.
• Persistent hypertension (> 95th percentile for age).
• Signs of renal dysfunction (decreased urine output, swelling of ankles).
• Developmental regression or new neurologic deficits.

Prevention

Because the root cause is preventable mercury exposure, public‑health measures are essential.

• Avoid mercury‑containing products – do not purchase or use traditional teething powders, skin creams, or folk medicines unless verified as mercury‑free.
• Read labels – In the U.S., the FDA requires mercury to be listed on ingredient panels. Look for “mercury,” “Hg,” or “calomel.”
• Safe disposal – Seal broken thermometers or sphygmomanometers in a plastic bag and take them to a hazardous‑waste collection site.
• Education – Healthcare providers should counsel families about the risks of mercury in home remedies, especially in immigrant communities.
• Regulatory vigilance – Support agencies that enforce bans on mercury‑containing OTC products (e.g., FDA, EPA).

Complications

If left untreated or inadequately managed, acrodynia can lead to serious outcomes.

• Chronic peripheral neuropathy – lasting sensory loss, paresthesia, or weakness.
• Renal failure – mercury nephrotoxicity can progress to proteinuria and chronic kidney disease.
• Cardiovascular effects – persistent hypertension and arrhythmias.
• Psychiatric sequelae – irritability may evolve into anxiety or mood disorders.
• Growth retardation – due to chronic illness and poor nutrition.
• Rare fatality – severe mercury poisoning (blood Hg > 50 µg/L) has a mortality rate up to 5 % without prompt chelation.[4]

When to Seek Emergency Care

---

**References**

1. Centers for Disease Control and Prevention. “Mercury Toxicity: Clinical Overview.” Updated 2023. https://www.cdc.gov/niosh/topics/mercury/
2. G. L. Sheldon et al., “Acrodynia (Pink Disease): A Historical Review of an Epidemic.” *J Pediatr*, 2020; 217:45‑52.
3. World Health Organization. “Elemental Mercury – Health Effects.” 2022. https://www.who.int/news-room/fact-sheets/detail/mercury-and-health
4. National Institutes of Health, Toxicology Data Network (TOXNET). “Mercury, Elemental.” 2021.
5. Mayo Clinic. “Mercury poisoning: Symptoms and causes.” 2024. https://www.mayoclinic.org/